Terence Friedlander, MD

Robert and Virginia O'Reilly Family Endowed Professorship of Medicine, UCSF

Chief of Hematology-Oncology at Zuckerberg San Francisco General; Associate Director for Cancer Research at ZSFG, Helen Diller Family Comprehensive Cancer Center; Associate Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

I am a medical oncologist and clinical investigator specializing in urologic cancers, specifically bladder and prostate cancers, and during my career I have focused on designing and carrying out clinical trials for patients affected by these cancers. In 2017 I became the Chief of the Division of Hematology and Oncology at Zuckerberg San Francisco General Hospital and Trauma Center in order build a clinical research program focused on making cancer clinical trials accessible to all patients in the city, including those most underserved, and in promoting health outcomes research by our investigators on campus. To that end we have built a multidisciplinary team consisting of clinician-investigators, health outcomes and disparities researchers, clinical research personnel, and patient navigators and health educators, in order to lower barriers to clinical trial participation by our diverse pool of patients.

My ultimate goal is to apply lessons learned from more than a decade of work as a clinical investigator to further grow the connections between the HDFCCC and the ZSFG cancer research program, promote both intramural and extramural collaborations, provide resources and support for junior faculty to grow their careers, lower barriers and increase access to novel therapies for our patients, learn about how novel therapies work in ethnically and racially diverse populations, and improve health outcomes for all our patients.

Education

Brown University, BA, 5/99
New York University School of Medicine, 2003, MD
UCSF Medical Center, 2003-2006, Residency
Utrecht University, Netherlands, 2007, Medical Ethics
UCSF Medical Center, 2007-2010, Oncology Fellowship

Honors & Awards

  • 2006
    Fullbright Scholarship in Medical Ethics, Netherlands-America Foundation
  • 2010
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2011
    ASCO Merit Award, American Society of Clinical Oncology
  • 2012
    Physician Research Training Aaward, United States Department of Defense
  • 2012
    Young Investigator Award, Prostate Cancer Foundation
  • 2012
    Young Investigator Travel Award, Advances in Circulating Tumor Cells Symposium
  • 2019
    UCSF Division of Hematology and Oncology Teaching Award

Selected Publications

  1. Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Flechon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study. Clin Cancer Res. 2023 Aug 31.  View on PubMed
  2. O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 09 01; 41(25):4107-4117.  View on PubMed
  3. Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR Cancer. 2023 Jun 01; 9:e45432.  View on PubMed
  4. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 May 17.  View on PubMed
  5. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089.  View on PubMed
  6. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11.  View on PubMed
  7. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15.  View on PubMed
  8. Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 01 01; 41(1):22-31.  View on PubMed
  9. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.  View on PubMed
  10. Friedlander TW. When to use somatic tumor testing in prostate cancer. Clin Adv Hematol Oncol. 2022 08; 20(8):487-489.  View on PubMed
  11. Idossa D, Friedlander T, Paller CJ, Ryan CJ, Borno HT. Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review. Front Oncol. 2022; 12:910115.  View on PubMed
  12. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539.  View on PubMed
  13. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706.  View on PubMed
  14. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718.  View on PubMed
  15. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658.  View on PubMed
  16. Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Clin Genitourin Cancer. 2022 04; 20(2):189-194.  View on PubMed
  17. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 Mar 15; 128(6):1194-1205.  View on PubMed
  18. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070.  View on PubMed
  19. Wong ML, Shi Y, Smith AK, Miaskowski C, Boscardin WJ, Cohen HJ, Lam V, Mazor M, Metzger L, Presley CJ, Williams GR, Loh KP, Ursem CJ, Friedlander TW, Blakely CM, Gubens MA, Allen G, Shumay D, Walter LC. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. J Am Geriatr Soc. 2022 01; 70(1):136-149.  View on PubMed
  20. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 10; 39(10):730.e9-730.e15.  View on PubMed

Go to UCSF Profiles, powered by CTSI